Treatment Patterns and Outcomes for Patients with Advanced Melanoma in US Oncology Clinical Practices

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Aim: To describe recent evolution in treatment patterns and outcomes for advanced melanoma (AMel). Methods: This retrospective observational study analyzed de-identified electronic health record data from the Flatiron Health database for 1140 adult patients who initiated first-line therapy for AMel from 1 January 2014 to 30 June 2016 with follow-up through 28 February 2017. Results: The most common first-line regimens were ipilimumab-based therapies (34%), anti-PD1 monotherapy (26%) and BRAF/MEK inhibitor(s) (20%). First-line ipilimumab-based and BRAF inhibitor regimens decreased after the third quarter of 2014 (3Q2014), and by 2Q2016, 55 and 91% of BRAF-mutant and BRAF wild-type cohorts, respectively, received a first-line anti-PD1 regimen. Median overall survival from first-line initiation for all patients was 18.8 months (95% CI: 16.3–23.3). Conclusion: Results illustrate changing paradigms of therapy and real-world patient outcomes for AMel.
Funding Information
  • Merck&Co., Inc.

This publication has 44 references indexed in Scilit: